Open Orphan #ORPH – Final results Reveal Record revenues and EBITDA-profitability accompanied by significant operational progress
Open Orphan (AIM: ORPH), a rapidly growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease products using human challenge clinical trials, announces its audited final results for the 12 months ended 31 December 2021. Financial highlights · Record revenues of £39.0m (2020: £22.2m) achieved representing 76% growth · […]
Open Orphan #ORPH – Notice of results
Open Orphan plc (AIM: ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials , announces that it will release its full year results for the year ended 31 December 2021 on Tuesday 7 June 2022. Investor Presentation Yamin ‘Mo’ Khan, Chief Executive […]
UK Investor Magazine Podcast, we discuss #stagflation, Burberry #BRBY Open Orphan #ORPH & Tertiary Minerals #TYM
The UK Investor Magazine is joined by Alan Green for a rundown of key market themes and Uk equities. We start by looking at Stagflation at the implications for the UK economy and markets. Stagflation is a period of rising inflation, economic contraction, and rising unemployment. The UK satisfies the first two of these, […]
Open Orphan #ORPH – £7.3m Influenza human challenge study contract win
Open Orphan (AIM: ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, announces that hVIVO, a subsidiary of Open Orphan, has signed a £7.3m influenza human challenge study (“Study”) contract with a leading biotechnology company to test its antiviral product […]
Open Orphan #ORPH – Proposal to purchase Poolbeg Pharma shares from distribution in specie shareholders
Open Orphan (ORPH) a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, notes the announcement dated 11 April 2022 from Poolbeg Pharma plc (“Poolbeg”), regarding a number of new investors (“New Investors”) having expressed interest in acquiring up to £1.6m of […]
Open Orphan #ORPH – Presentation at World Vaccine Congress
Presentation at World Vaccine Congress hVIVO presents on the outcomes from the world’s first COVID-19 characterisation study Open Orphan plc (AIM: ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, announces that Dr Andrew Catchpole, Chief Scientific Officer of hVIVO, a subsidiary of Open […]
Open Orphan #ORPH – COVID-19 Characterisation Study peer reviewed results published in industry leading periodical Nature Medicine
Open Orphan (AIM: ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, announces that the results from the world’s first COVID-19 characterisation study have been peer reviewed and published in the scientific journal Nature Medicine. ‘Safety, tolerability and viral kinetics […]
Open Orphan #ORPH – Trading Update, Volunteer Recruitment and Laboratory Facilities Expansion
Open Orphan plc (AIM: ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, provides a trading update for the year ended 31 December 2021. The Company also announces it will be opening a new primary FluCamp volunteer recruitment screening facility […]
Open Orphan #ORPH – Investor presentations to provide introduction to new CEO Yamin ‘Mo’ Khan
Open Orphan (AIM: ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, announces it will provide two live investor presentations in March 2022. The presentations will provide investors with an introduction to new Chief Executive Officer, Yamin ‘Mo’ Khan, who will […]
Open Orphan #ORPH – FDA Breakthrough Designation for Big Pharma RSV candidate
Vaccine candidate assessed in successful human challenge trial conducted by hVIVO Open Orphan plc (AIM: ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, notes the announcement dated 14 February 2022 from Bavarian Nordic A/S (“Bavarian Nordic”) (OMX: BAVA), reporting […]